Literature DB >> 15459678

Prion diseases--close to effective therapy?

Neil R Cashman1, Byron Caughey.   

Abstract

The transmissible spongiform encephalopathies could represent a new mode of transmission for infectious diseases--a process more akin to crystallization than to microbial replication. The prion hypothesis proposes that the normal isoform of the prion protein is converted to a disease-specific species by template-directed misfolding. Therapeutic and prophylactic strategies to combat these diseases have emerged from immunological and chemotherapeutic approaches. The lessons learned in treating prion disease will almost certainly have an impact on other diseases that are characterized by the pathological accumulation of misfolded proteins.

Entities:  

Mesh:

Year:  2004        PMID: 15459678     DOI: 10.1038/nrd1525

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  31 in total

1.  Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo.

Authors:  David A Kocisko; Byron Caughey
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  A porphyrin increases survival time of mice after intracerebral prion infection.

Authors:  David A Kocisko; Winslow S Caughey; Richard E Race; Grant Roper; Byron Caughey; John D Morrey
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner.

Authors:  Yuri Kawasaki; Keiichi Kawagoe; Chun-jen Chen; Kenta Teruya; Yuji Sakasegawa; Katsumi Doh-ura
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

4.  A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.

Authors:  N C Ferreira; L M Ascari; A G Hughson; G R Cavalheiro; C F Góes; P N Fernandes; J R Hollister; R A da Conceição; D S Silva; A M T Souza; M L C Barbosa; F A Lara; R A P Martins; B Caughey; Y Cordeiro
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

5.  Prions Strongly Reduce NMDA Receptor S-Nitrosylation Levels at Pre-symptomatic and Terminal Stages of Prion Diseases.

Authors:  Elisa Meneghetti; Lisa Gasperini; Tommaso Virgilio; Fabio Moda; Fabrizio Tagliavini; Federico Benetti; Giuseppe Legname
Journal:  Mol Neurobiol       Date:  2019-02-01       Impact factor: 5.590

6.  Temporal Resolution of Misfolded Prion Protein Transport, Accumulation, Glial Activation, and Neuronal Death in the Retinas of Mice Inoculated with Scrapie.

Authors:  M Heather West Greenlee; Melissa Lind; Robyn Kokemuller; Najiba Mammadova; Naveen Kondru; Sireesha Manne; Jodi Smith; Anumantha Kanthasamy; Justin Greenlee
Journal:  Am J Pathol       Date:  2016-08-09       Impact factor: 4.307

7.  The distribution of four trace elements (Fe, Mn, Cu, Zn) in forage and the relation to scrapie in Iceland.

Authors:  Tryggvi Eiríksson; Hólmgeir Björnsson; Kristín Björg Gudmundsdóttir; Jakob Kristinsson; Torkell Jóhannesson
Journal:  Acta Vet Scand       Date:  2010-05-21       Impact factor: 1.695

8.  Effects of Various Flavonoids on the α-Synuclein Fibrillation Process.

Authors:  Xiaoyun Meng; Larissa A Munishkina; Anthony L Fink; Vladimir N Uversky
Journal:  Parkinsons Dis       Date:  2010-01-28

9.  Calcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survival.

Authors:  Abhisek Mukherjee; Diego Morales-Scheihing; Dennisse Gonzalez-Romero; Kristi Green; Giulio Taglialatela; Claudio Soto
Journal:  PLoS Pathog       Date:  2010-10-07       Impact factor: 6.823

10.  Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria.

Authors:  Christine Vande Velde; Timothy M Miller; Neil R Cashman; Don W Cleveland
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.